Patents by Inventor Tim Beaumont

Tim Beaumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES
    Publication number: 20160096881
    Abstract: The invention provides means and methods for producing high-affinity antibodies against an antigen of interest, usually stable B-cell cultures.
    Type: Application
    Filed: December 2, 2015
    Publication date: April 7, 2016
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Hergen SPITS, Adrianus Quirinus BAKKER, Koen WAGNER
  • RSV specific binding molecule
    Patent number: 9283274
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: March 15, 2016
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS
    Publication number: 20160060598
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Application
    Filed: August 26, 2015
    Publication date: March 3, 2016
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • Means and methods for producing high affinity antibodies
    Patent number: 9273118
    Abstract: The invention provides means and methods for modulating the occurrence of somatic hypermutations in antibody producing plasmablast-like B-cells.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: March 1, 2016
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Hergen Spits, Mark J. Kwakkenbos, Adrianus Q. Bakker
  • Gram-positive bacteria specific binding compounds
    Patent number: 9266943
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: February 23, 2016
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20150376266
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: June 2, 2015
    Publication date: December 31, 2015
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • Means and methods for producing high affinity antibodies
    Patent number: 9206247
    Abstract: Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: December 8, 2015
    Assignee: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • Means and methods for influencing the stability of antibody producing cells
    Patent number: 9127251
    Abstract: The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: September 8, 2015
    Assignees: ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM, AIMM THERAPEUTICS B.V.
    Inventors: Hergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
  • Gram-positive bacteria specific binding compounds
    Patent number: 9090677
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • INFLUENZA A VIRUS SPECIFIC ANTIBODIES
    Publication number: 20150010566
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: December 3, 2012
    Publication date: January 8, 2015
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • RSV G PROTEIN SPECIFIC ANTIBODIES
    Publication number: 20150004155
    Abstract: The disclosure relates to human isolated, synthetic or recombinant antibodies or functional parts thereof, specific for the RSV G protein. Antibodies specific for the RSV G protein are particularly suitable for counteracting RSV and symptoms, such as inflammation, resulting from an RSV infection. The disclosure further relates to the use of such RSV G-specific antibodies for diagnosis of an RSV infection and as a medicament and/or prophylactic agent for, at least in part, treating or alleviating symptoms of a Respiratory Syncytial Virus infection and/or a Respiratory Syncytial Virus related disorder.
    Type: Application
    Filed: November 16, 2012
    Publication date: January 1, 2015
    Applicant: AIMM THERAPEUTICS B.V.
    Inventors: Tim Beaumont, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20140377279
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: December 25, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20140235828
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: December 11, 2013
    Publication date: August 21, 2014
    Applicants: AIMM THERAPEUTICS B.V., GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA
  • RSV SPECIFIC BINDING MOLECULE
    Publication number: 20140093500
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: MEDIMMUNE LIMITED
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM
    Publication number: 20140072575
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 13, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Gram-positive bacteria specific binding compounds
    Patent number: 8617556
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: December 31, 2013
    Assignees: Genentech, Inc., AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • MEANS AND METHODS FOR PRODUCING HIGH AFFINITY ANTIBODIES
    Publication number: 20130331552
    Abstract: Described are means and methods for producing high-affinity antibodies against an antigen of interest, using stable B-cell cultures.
    Type: Application
    Filed: December 2, 2011
    Publication date: December 12, 2013
    Applicant: AIMM Therapeutics B.V.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Hergen Spits, Adrianus Quirinus Bakker, Koen Wagner
  • RSV specific binding molecule
    Patent number: 8568726
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: October 29, 2013
    Assignee: MedImmune Limited
    Inventors: Tim Beaumont, Adrianus Bakker, Etsuko Yasuda
  • RSV-specific binding molecules and means for producing them
    Patent number: 8562996
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Grant
    Filed: May 30, 2008
    Date of Patent: October 22, 2013
    Assignee: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont
  • GRAM-POSITIVE BACTERIA SPECIFIC BINDING COMPOUNDS
    Publication number: 20130261293
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Application
    Filed: March 5, 2013
    Publication date: October 3, 2013
    Applicant: GENENTECH, INC.
    Inventors: Tim BEAUMONT, Mark Jeroen KWAKKENBOS, Eric J. BROWN, John Hiroshi MORISAKI, Wouter L.W. HAZENBOS, Sanjeev MARIATHASAN, Kimberly KAJIHARA, Yi XIA